NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

ABSTRACT:

Objectives

NY-ESO-1 is a cancer testis antigen and a promising target for immunotherapy. The purpose of this study was to determine the expression frequency, immunogenicity, and clinical impact of NY-ESO-1 in ovarian cancer.

Methods

Immunohistochemistry (IHC), reverse-transcription polymerase chain reaction (RT-PCR), and quantitative-PCR (qRT-PCR) were utilized in an ovarian cancer (including Fallopian tube and primary peritoneal cancers) patient cohort; humoral responses against NY-ESO-1 were determined by ELISA. Clinicopathologic outcomes including progression-free (PFS) and overall (OS) survival were evaluated based on NY-ESO-1 expression. Cohen's kappa (κ) tested agreement between expression tests.

Results

NY-ESO-1 expression was detected by any method in 40.7% of

SUBMITTER: Szender JB 

PROVIDER: S-EPMC5497581 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature